Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder

NCT07184840 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorder Attack

Interventions

DRUG: Intravenous Methylprednisolone (IVMP)
DRUG: Complement protein C5 inhibitor

Sponsor

Tianjin Medical University General Hospital